The development of gene therapies for the treatment of cancer has generally relied upon two strategies. The first is the expression of a therapeutic transgene from a replication-defective (RD) viral ...
We have previously described oncolytic adenovirus (Ad) vectors KD3 and KD3–interferon (IFN) that were rendered cancer-specific by mutations in the E1A region of Ad; these mutations abolish binding of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback